TILDRAKIZUMAB-ASMN

2410 reported adverse events

Drug classes: Interleukin-23 Antagonist [EPC]

These side effects are most commonly reported by patients taking TILDRAKIZUMAB-ASMN:

# Side effect Count
0 PRODUCT DOSE OMISSION ISSUE 489
1 DRUG INEFFECTIVE 313
2 INTENTIONAL DOSE OMISSION 215
3 DEATH 167
4 CONDITION AGGRAVATED 121
5 PSORIASIS 109
6 OFF LABEL USE 96
7 SELF-MEDICATION 92
8 PRURITUS 89
9 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 86
See all common reactions for TILDRAKIZUMAB-ASMN

TILDRAKIZUMAB-ASMN is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 SELF-MEDICATION 92 0.0224
1 TREATMENT DELAYED 24 0.0139
2 INTENTIONAL DOSE OMISSION 215 0.0075
3 WEST NILE VIRAL INFECTION 4 0.0053
4 GUTTATE PSORIASIS 3 0.0037
5 PRODUCT DOSE OMISSION ISSUE 489 0.0017
6 THERAPY CESSATION 85 0.0017
7 CUTANEOUS T-CELL LYMPHOMA 2 0.0016
8 DERMATITIS EXFOLIATIVE GENERALISED 5 0.0014
9 PRODUCT LEAKAGE 8 0.0014
See all enriched reactions for TILDRAKIZUMAB-ASMN